Dr. Reddy's Laboratories announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration
(USFDA).
The Aggrenox brand and generic had U.S. sales of approximately $182 million MAT for the most recent twelve months ending in October 2018 according to IMS Health.
Dr. Reddy's Aspirin and Extended-Release Dipyridamole Capsules is available in 25 mg/200 mg strength with 60 count bottle size.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
